Novavax signs COVID-19 license deal with Sanofi, removes doubt about business viability PARIS (Reuters) -Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker’s market value. In February […]
This post first appeared on Global Banking And Finance Review Magazine – Fin, please read the originial post: here
